By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDxHealth said today that Celldex Therapeutics will use its epigenetic MGMT test during recruitment of patients for a Phase III clinical study of Celldex's immunotherapeutic vaccine, rindopepimut, in newly diagnosed glioblastoma multiforme.

The study is expected to recruit 374 patients with newly diagnosed EGFRvIII-expressing GBM, an aggressive form of brain cancer, following gross total resection at more than 150 global clinical sites.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.